Akari Therapeutics PLC (AKTX) — 8-K Filings

All 8-K filings from Akari Therapeutics PLC. Browse 32 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (32)

8-K Filing — Dec 17, 2025
Akari Therapeutics Files 8-K on Shareholder Votes & Financials — Dec 16, 2025 Risk: low
Akari Therapeutics Plc filed an 8-K on December 15, 2025, reporting on matters submitted to a vote of security holders and financial statements. The company, fo
8-K Filing — Dec 8, 2025
Akari Therapeutics Faces Delisting Concerns — Nov 26, 2025 Risk: high
Akari Therapeutics Plc filed an 8-K on November 26, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the e
Akari Therapeutics Files 8-K: Officer/Director Changes & Financials — Oct 23, 2025 Risk: medium
Akari Therapeutics Plc filed an 8-K on October 23, 2025, reporting events as of October 22, 2025. The filing indicates changes related to the departure of direc
Akari Therapeutics Files 8-K: Material Agreement & Equity Update — Oct 16, 2025 Risk: medium
Akari Therapeutics Plc entered into a material definitive agreement on October 14, 2025. The company also reported on unregistered sales of equity securities an
Akari Therapeutics Files 8-K — Oct 15, 2025 Risk: low
Akari Therapeutics Plc filed an 8-K on October 15, 2025, reporting on financial statements and exhibits. The company, formerly known as Celsus Therapeutics Plc
Akari Therapeutics to Acquire 03 Life Sciences — Sep 29, 2025 Risk: medium
Akari Therapeutics Plc announced on September 26, 2025, that it has entered into a definitive agreement to acquire all outstanding shares of 03 Life Sciences. T
Akari Therapeutics Enters Material Definitive Agreement — Sep 25, 2025 Risk: medium
Akari Therapeutics Plc entered into a material definitive agreement on September 19, 2025. The company, formerly known as Celsus Therapeutics Plc and Morria Bio
Akari Therapeutics Files 8-K: Agreements, Equity Sales, and Board Changes — Aug 29, 2025 Risk: medium
Akari Therapeutics Plc announced on August 28, 2025, an entry into a material definitive agreement. The company also reported on unregistered sales of equity se
Akari Therapeutics Enters and Terminates Agreements — Aug 21, 2025 Risk: medium
Akari Therapeutics Plc entered into a material definitive agreement on August 15, 2025. The company also terminated a material definitive agreement on the same
8-K Filing — Aug 19, 2025
Akari Therapeutics Files 8-K: Officer Changes & Shareholder Votes — Jul 1, 2025 Risk: medium
Akari Therapeutics Plc filed an 8-K on July 1, 2025, reporting events as of June 30, 2025. The filing indicates changes in directors or officers, the appointmen
Akari Therapeutics Files 8-K on Financials — May 15, 2025 Risk: low
Akari Therapeutics Plc filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition. The filing also includes financial statemen
Akari Therapeutics Files 8-K on Operations — Apr 16, 2025 Risk: low
Akari Therapeutics Plc filed an 8-K on April 16, 2025, reporting on its results of operations and financial condition, and including financial statements and ex
Akari Therapeutics Announces Director Changes — Mar 20, 2025 Risk: low
Akari Therapeutics Plc announced on March 14, 2025, the departure of Director Dr. Jonathan Solomon and the appointment of Dr. Philip Astley-Sparke as a new dire
Akari Therapeutics Files 8-K: Material Agreement & Equity Sales — Mar 3, 2025 Risk: medium
Akari Therapeutics Plc announced on March 2, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of equi
Akari Therapeutics Plc Files 8-K — Jan 13, 2025 Risk: low
Akari Therapeutics Plc announced a Regulation FD Disclosure on January 13, 2025. The company, formerly known as Celsus Therapeutics Plc and Morria Biopharmaceut
Akari Therapeutics Board Changes Announced — Dec 18, 2024 Risk: medium
Akari Therapeutics Plc announced on December 12, 2024, a change in its board of directors. Dr. Clive Meanwell has been appointed as a new director, and Dr. Pete
Akari Therapeutics Appoints New CMO, Adds Director — Dec 16, 2024 Risk: medium
Akari Therapeutics Plc announced on December 12, 2024, the appointment of Dr. Robert J. Spiegel as Chief Medical Officer and the election of Ms. Jennifer L. McN
Akari Therapeutics Announces Board and Executive Changes — Dec 12, 2024 Risk: medium
Akari Therapeutics Plc announced on December 6, 2024, changes in its board of directors and executive compensation. Specifically, the company reported the depar
Akari Therapeutics Plc Files 8-K with Multiple Material Events — Nov 14, 2024 Risk: high
Akari Therapeutics Plc announced on November 13, 2024, that it has entered into a material definitive agreement related to the completion of an acquisition or d
Akari Therapeutics Files 8-K on Shareholder Votes and Filings — Nov 8, 2024 Risk: low
Akari Therapeutics Plc filed an 8-K on November 7, 2024, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial
Akari Therapeutics Faces Nasdaq Delisting Warning — Oct 4, 2024 Risk: medium
Akari Therapeutics Plc announced on October 1, 2024, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing rules due to
Akari Therapeutics Appoints New CMO, Elects Director — Sep 18, 2024 Risk: medium
Akari Therapeutics Plc announced on September 13, 2024, the appointment of Dr. Jonathan Solomon as Chief Medical Officer and the election of Ms. Sarah O'Connor
Akari Therapeutics Files 8-K on Financing and Warrants — Sep 6, 2024 Risk: medium
Akari Therapeutics Plc filed an 8-K on September 6, 2024, reporting on other events and financial statements. The filing references various financing activities
Akari Therapeutics Plc Files 8-K on Shareholder Vote — Jul 1, 2024 Risk: low
Akari Therapeutics Plc filed an 8-K on July 1, 2024, reporting on a matter submitted to a vote of security holders as of June 28, 2024. The filing details the c
Akari Therapeutics Files 8-K on Officer/Director Changes — Jun 5, 2024 Risk: medium
Akari Therapeutics Plc filed an 8-K on June 5, 2024, reporting events as of May 31, 2024. The filing primarily concerns the departure of directors or certain of
Akari Therapeutics Enters Definitive Agreement, Discloses Equity Sales — Jun 4, 2024 Risk: medium
Akari Therapeutics Plc announced on May 29, 2024, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equity
Akari Therapeutics Files 8-K on Financials — May 16, 2024 Risk: low
Akari Therapeutics Plc filed an 8-K on May 16, 2024, reporting on its results of operations and financial condition. The filing includes financial statements an
Akari Therapeutics Announces CMO Departure, Appoints Interim — May 7, 2024 Risk: medium
Akari Therapeutics Plc announced on May 1, 2024, the departure of its Chief Medical Officer, Dr. Robert James, and the appointment of Dr. Jonathan Solomon as in
Akari Therapeutics Director Departs, Files 8-K — May 1, 2024 Risk: low
Akari Therapeutics Plc announced on April 25, 2024, the departure of Dr. Robert L. Finberg from its Board of Directors. The company also reported on compensator

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX